Eli Lilly disclosed a new series of RXFP1 (relaxin receptor 1) agonists in a recent patent disclosure, positioning the compounds across indications that include pulmonary hypertension, chronic obstructive pulmonary disease and kidney disease. The company reported synthesis and preliminary activity data in the filing, signalling an expansion of its small‑molecule pipeline. RXFP1 is a G‑protein coupled receptor implicated in vasodilation and tissue remodeling; agonists aim to leverage those pathways in cardiopulmonary and renal disease. The disclosure lists chemical series and claimed therapeutic utility, a typical step before more advanced pharmacology or partnering discussions. Industry watchers will track whether Lilly advances these molecules into lead optimization or explores external collaborations for clinical development.